Takeda is ‘not in favor’ of MFN, CEO-designate says
Takeda’s incoming CEO took a firm stance against President Donald Trump’s “most favored nation” deals with drugmakers on Thursday, while Sanofi and Roche shared new details about their negotiations with the White House.
“In general ...
⚠️ 风险分析 中
摘要：武田制药反对美国MFN药品定价政策，可能影响药企在美市场准入与定价。
影响：若美国推行MFN政策，可能迫使在华外企调整全球定价策略，或影响其在中国市场的价格谈判与利润空间。
建议：制药企业应评估美国政策对全球定价的连锁影响，加强与中国监管机构的沟通，准备应对潜在的价格压力。
「素履以往」
Not the sharpest mind, but the steadiest hand.
Not the sharpest mind, but the steadiest hand.